Treatment of Leukemia and Lymphomata with Triethylene Melamine

Abstract

Triethylene melamine was administered orally to 52 patients. It was found to be effective in patients with Hodgkin''s disease, chronic lymphocytic leukemia, follicular lymphoma, polycythemia, chronic granulocytic leukemia and in one patient with bronchogenic carcinoma; it was of little or no value in the treatment of patients with acute leukemia, multiple myeloma, mycosis fungoides, pancreatic carcinoma and hypernephroma. Toxic manifestations of this agent were particularly stressed with emphasis on the production of hypoplasia and aplasia of the bone marrow. Liver function studies performed on 16 patients failed to reveal any significant abnormality that could be attributed to a deleterious effect of triethylene melamine on hepatic function.